C Albus1, F Geiser2. 1. Klinik und Poliklinik für Psychosomatik und Psychotherapie, Uniklinik Köln, Köln, Deutschland. christian.albus@uk-koeln.de. 2. Klinik und Poliklinik für Psychosomatik und Psychotherapie, Universitätsklinikum Bonn, Bonn, Deutschland.
Abstract
BACKGROUND: Comorbid depression is frequent in internal medicine (e.g. in coronary heart disease, congestive heart failure or diabetes mellitus) and impairs quality of life as well as the prognosis of the somatic illness. AIM: To review evidence based recommendations for the treatment of depressive comorbidity in selected somatic disorders. MATERIALS AND METHODS: Selective literature search based on national and international guidelines. RESULTS: In clinical routine, depressive symptoms are often overseen or misinterpreted. Therefore, a specific diagnostic is recommended. Depressive symptoms should obligatory be screened during the clinical interview or by validated questionnaires. When screened positive, further diagnostic steps are mandatory. The treatment of depressive disorders has three main components: basic psychosomatic care, psychotherapy and antidepressant medication. These interventions are safe and effective for reducing depressive symptoms and enhancing quality of life. However, results regarding the effects on morbidity and mortality of the comorbid somatic disorder are still inconclusive. The greatest effects on depression are obtained by a preference-based, stepped-care approach and an optimal cooperation of all professionals ("collaborative care"). CONCLUSIONS: An effective treatment of depressive comorbidity is relevant for quality of life and possibly also for the prognosis of a somatic disease. Integrating a routine screening for depressive symptoms is the first step toward an effective, evidence-based therapy.
BACKGROUND: Comorbid depression is frequent in internal medicine (e.g. in coronary heart disease, congestive heart failure or diabetes mellitus) and impairs quality of life as well as the prognosis of the somatic illness. AIM: To review evidence based recommendations for the treatment of depressive comorbidity in selected somatic disorders. MATERIALS AND METHODS: Selective literature search based on national and international guidelines. RESULTS: In clinical routine, depressive symptoms are often overseen or misinterpreted. Therefore, a specific diagnostic is recommended. Depressive symptoms should obligatory be screened during the clinical interview or by validated questionnaires. When screened positive, further diagnostic steps are mandatory. The treatment of depressive disorders has three main components: basic psychosomatic care, psychotherapy and antidepressant medication. These interventions are safe and effective for reducing depressive symptoms and enhancing quality of life. However, results regarding the effects on morbidity and mortality of the comorbid somatic disorder are still inconclusive. The greatest effects on depression are obtained by a preference-based, stepped-care approach and an optimal cooperation of all professionals ("collaborative care"). CONCLUSIONS: An effective treatment of depressive comorbidity is relevant for quality of life and possibly also for the prognosis of a somatic disease. Integrating a routine screening for depressive symptoms is the first step toward an effective, evidence-based therapy.
Authors: M A Busch; U E Maske; L Ryl; R Schlack; U Hapke Journal: Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz Date: 2013-05 Impact factor: 1.513
Authors: Massimo F Piepoli; Arno W Hoes; Stefan Agewall; Christian Albus; Carlos Brotons; Alberico L Catapano; Marie-Therese Cooney; Ugo Corrà; Bernard Cosyns; Christi Deaton; Ian Graham; Michael Stephen Hall; F D Richard Hobbs; Maja-Lisa Løchen; Herbert Löllgen; Pedro Marques-Vidal; Joep Perk; Eva Prescott; Josep Redon; Dimitrios J Richter; Naveed Sattar; Yvo Smulders; Monica Tiberi; H Bart van der Worp; Ineke van Dis; W M Monique Verschuren; Simone Binno Journal: Eur Heart J Date: 2016-05-23 Impact factor: 29.983
Authors: Christian Albus; Christoph Herrmann-Lingen; Katrin Jensen; Matthes Hackbusch; Nina Münch; Catharina Kuncewicz; Maurizio Grilli; Bernhard Schwaab; Bernhard Rauch Journal: Eur J Prev Cardiol Date: 2019-03-11 Impact factor: 7.804